Company news
Equillium, Inc. (NASDAQ:EQ) news
Equillium, Inc. news releases on 6ix. Latest, Dec 21, 2023: Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia…
Press releases — page 2
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
December 20, 2023
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
November 12, 2023
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
November 7, 2023
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
November 5, 2023
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
October 18, 2023
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium
October 15, 2023
Equillium to Host Analyst & Investor Day
October 2, 2023
Equillium to Present at the JonesTrading 2023 Healthcare Summit
October 1, 2023
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
September 19, 2023
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
August 29, 2023
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
August 8, 2023
Equillium Announces $7.5 Million Share Repurchase Program
August 1, 2023
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
May 31, 2023
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
May 10, 2023
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
April 23, 2023
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
March 22, 2023
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
March 21, 2023
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
February 16, 2023
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
February 6, 2023
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 12, 2023
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
December 22, 2022
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 15, 2022
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
December 5, 2022
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
November 13, 2022
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
November 13, 2022
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
November 9, 2022
Equillium to Present at Two Upcoming Investor Conferences
November 7, 2022
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
November 2, 2022
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
November 1, 2022
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
October 25, 2022
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
September 26, 2022
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
September 14, 2022
Equillium to Acquire Metacrine in All-Stock Transaction
September 5, 2022
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
August 14, 2022
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
July 27, 2022
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
May 11, 2022
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
May 11, 2022
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
May 8, 2022
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
April 24, 2022
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
April 3, 2022
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
March 22, 2022
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
March 22, 2022
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease
March 3, 2022
Equillium Announces Appointment of Barbara Troupin to Board of Directors
February 28, 2022
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
February 15, 2022
Equillium Provides Timing Update on Conference Presentations
February 14, 2022
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
February 8, 2022
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
January 9, 2022
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 4, 2022
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
January 3, 2022